Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells

Physiological characterization and quantitative proteomic analyses of metabolically engineered E. coli K4 strains with improved pathways for capsular polysaccharide biosynthesis

(2018) Donatella Cimini et al.   BIOTECHNOLOGY AND BIOENGINEERING

Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

(2018) Filip Mundt et al.   CANCER RESEARCH

RIP1–HAT1–SIRT Complex Identification and Targeting in Treatment and Prevention of Cancer

(2018) Vincenzo Carafa et al.   CLINICAL CANCER RESEARCH

Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells

(2018) Seul-Ki Cheon et al.   Molecular Oncology

Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation

(2017) Stefania Napolitano et al.   Oncotarget

Deep Phospho- and Phosphotyrosine Proteomics Identified Active Kinases and Phosphorylation Networks in Colorectal Cancer Cell Lines Resistant to Cetuximab

(2017) Yuichi Abe et al.   Scientific Reports

Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer

(2016) Ji-Young Jang et al.   MOLECULAR CANCER THERAPEUTICS

Macrophage Migration Inhibitory Factor (MIF): Biological Activities and Relation with Cancer

(2016) Camila Cristina Guimarães Nobre et al.   PATHOLOGY & ONCOLOGY RESEARCH

Mechanisms of resistance to anti-EGFR therapy in colorectal cancer

(2016) Ben Zhao et al.   Oncotarget

Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab

(2015) S. Napolitano et al.   CLINICAL CANCER RESEARCH

Macrophage migration inhibitory factor: A key cytokine and therapeutic target in colon cancer

(2015) A.N. Gordon-Weeks et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Metastatic Colorectal Cancer: Current State and Future Directions

(2015) Marwan G. Fakih   JOURNAL OF CLINICAL ONCOLOGY

The genomic landscape of response to EGFR blockade in colorectal cancer

(2015) Andrea Bertotti et al.   NATURE

Identification of proteins responsible for adriamycin resistance in breast cancer cells using proteomics analysis

(2015) Zhipeng Wang et al.   Scientific Reports

Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition

(2014) T. Troiani et al.   CLINICAL CANCER RESEARCH

Molecular Aspects of Resistance to Biological and Non-Biological Drugs and Strategies to Overcome Resistance in Colorectal Cancer

(2014) T. Troiani et al.   CURRENT MEDICINAL CHEMISTRY

Macrophage migratory inhibitory factor promotes bladder cancer progression via increasing proliferation and angiogenesis

(2013) Shilpa Choudhary et al.   CARCINOGENESIS

Increased TGF-  as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR-MET Interaction and Activation of MET Signaling in Colon Cancer Cells

(2013) T. Troiani et al.   CLINICAL CANCER RESEARCH

KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy

(2013) Emanuele Valtorta et al.   INTERNATIONAL JOURNAL OF CANCER

Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer

(2013) Alberto Bardelli et al.   Cancer Discovery

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

(2012) Sandra Misale et al.   NATURE

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

(2012) Luis A. Diaz Jr et al.   NATURE

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab

(2011) Toni M. Brand et al.   CANCER BIOLOGY & THERAPY

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

(2011) K. Yonesaka et al.   Science Translational Medicine

Adenine nucleotide translocase 2 is a key mitochondrial protein in cancer metabolism

(2010) Arnaud Chevrollier et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS

Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer

(2010) F Di Fiore et al.   BRITISH JOURNAL OF CANCER

Autocrine Induction of Invasive and Metastatic Phenotypes by the MIF-CXCR4 Axis in Drug-Resistant Human Colon Cancer Cells

(2010) Anne-Frédérique Dessein et al.   CANCER RESEARCH

Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells

(2010) E. Martinelli et al.   CLINICAL CANCER RESEARCH

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

(2010) Jean-Yves Douillard et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer

(2009) Eva Verjans et al.   BMC CANCER

Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy

(2009) Scott Kopetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of a Putative Protein Profile Associated with Tamoxifen Therapy Resistance in Breast Cancer

(2009) Arzu Umar et al.   MOLECULAR & CELLULAR PROTEOMICS

Unknown

(2009) Xing-Xiang He et al.   MOLECULAR MEDICINE

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Novel, Macrophage Migration Inhibitory Factor Suicide Substrate Inhibits Motility and Growth of Lung Cancer Cells

(2008) M. Winner et al.   CANCER RESEARCH